|
1
|
Notani P: Global variation in cancer
incidence and mortality. Curr Sci. 81:465–475. 2001.
|
|
2
|
Holschneider CH and Berek JS: Ovarian
cancer: epidemiology, biology, and prognostic factors. Semin Surg
Oncol. 19:3–10. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cannistra SA, Ottensmeier C, Niloff J,
Orta B and DiCarlo J: Expression and function of beta 1 and alpha v
beta 3 integrins in ovarian cancer. Gynecol Oncol. 58:216–225.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cruet-Hennequart S, Maubant S, Luis J,
Gauduchon P, Staedel C and Dedhar S: alpha(v) integrins regulate
cell proliferation through integrin-linked kinase (ILK) in ovarian
cancer cells. Oncogene. 22:1688–1702. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ruseva Z, Geiger PX, Hutzler P, Kotzsch M,
Luber B, Schmitt M, Gross E and Reuning U: Tumor suppressor KAI1
affects integrin alphavbeta3-mediated ovarian cancer cell adhesion,
motility, and proliferation. Exp Cell Res. 315:1759–1771. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kaur S, Kenny HA, Jagadeeswaran S,
Zillhardt MR, Montag AG, Kistner E, Yamada SD, Mitra AK and Lengyel
E: {beta}3-integrin expression on tumor cells inhibits tumor
progression, reduces metastasis, and is associated with a favorable
prognosis in patients with ovarian cancer. Am J Pathol.
175:2184–2196. 2009.
|
|
7
|
Mulrooney J, Foley K, Vineberg S,
Barreuther M and Grabel L: Phosphorylation of the beta1 integrin
cytoplasmic domain: toward an understanding of function and
mechanism. Exp Cell Res. 258:332–341. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dedhar S, Williams B and Hannigan G:
Integrin-linked kinase (ILK): a regulator of integrin and
growth-factor signalling. Trends Cell Biol. 9:319–323. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
McDonald PC, Fielding AB and Dedhar S:
Integrin-linked kinase - essential roles in physiology and cancer
biology. J Cell Sci. 121:3121–3132. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ahmed N, Riley C, Oliva K, Stutt E, Rice
GE and Quinn MA: Integrin-linked kinase expression increases with
ovarian tumour grade and is sustained by peritoneal tumour fluid. J
Pathol. 201:229–237. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gao J, Zhu J, Li HY, Pan XY, Jiang R and
Chen JX: Small interfering RNA targeting integrin-linked kinase
inhibited the growth and induced apoptosis in human bladder cancer
cells. Int J Biochem Cell Biol. 43:1294–1304. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pontier SM, Huck L, White DE, Rayment J,
Sanguin-Gendreau V, Hennessy B, Zuo D, St-Arnaud R, Mills GB,
Dedhar S, et al: Integrin-linked kinase has a critical role in
ErbB2 mammary tumor progression: implications for human breast
cancer. Oncogene. 29:3374–3385. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chan J, Ko FC, Yeung YS, Ng IO and Yam JW:
Integrin-linked kinase overexpression and its oncogenic role in
promoting tumorigenicity of hepatocellular carcinoma. PLoS One.
6:e169842011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu Q, Xiao L, Yuan D, Shi X and Li P:
Silencing of the integrin-linked kinase gene induces the apoptosis
in ovarian carcinoma. J Recept Signal Transduct Res. 32:120–127.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hannigan G, Troussard AA and Dedhar S:
Integrin-linked kinase: a cancer therapeutic target unique among
its ILK. Nat Rev Cancer. 5:51–63. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang Y, Fukui K, Koike T and Zheng X:
Induction of autophagy in neurite degeneration of mouse superior
cervical ganglion neurons. Eur J Neurosci. 26:2979–2988. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
McDonald PC and Dedhar S: The role of
integrin-linked kinase in cancer development and progression.
Cell-Extracellular Matrix Interactions in Cancer. Zent R and Pozzi
A: Springer; New York: pp. 245–273. 2010, View Article : Google Scholar
|
|
18
|
Monteith DK, Geary RS, Leeds JM, Johnston
J, Monia BP and Levin AA: Preclinical evaluation of the effects of
a novel antisense compound targeting C-raf kinase in mice and
monkeys. Toxicol Sci. 46:365–375. 1998.PubMed/NCBI
|
|
19
|
Radeva G, Petrocelli T, Behrend E,
Leung-Hagesteijn C, Filmus J, Slingerland J and Dedhar S:
Overexpression of the integrin-linked kinase promotes
anchorage-independent cell cycle progression. J Biol Chem.
272:13937–13944. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Persad S, Attwell S, Gray V, Delcommenne
M, Troussard A, Sanghera J and Dedhar S: Inhibition of
integrin-linked kinase (ILK) suppresses activation of protein
kinase B/Akt and induces cell cycle arrest and apoptosis of
PTEN-mutant prostate cancer cells. Proc Natl Acad Sci USA.
97:3207–3212. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rayburn ER and Zhang R: Antisense, RNAi,
and gene silencing strategies for therapy: mission possible or
impossible? Drug Discov Today. 13:513–521. 2008. View Article : Google Scholar : PubMed/NCBI
|
